RecruitingNCT05800925

Triage Survey for Psychiatry Research Eligibility

Sponsor

Adams Clinical

Enrollment

20,000 participants

Start Date

Dec 21, 2021

Study Type

OBSERVATIONAL

Conditions

Major Depressive Disorder Generalized Anxiety Disorder Borderline Personality Disorder

Summary

TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Survey for people with borderline personality disorder, generalized anxiety disorder, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSurvey

Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.

Locations(6)

Adams Clinical, Boston

Boston, Massachusetts, United States

Adams Clinical, Watertown

Watertown, Massachusetts, United States

Adams Clinical, Harlem

New York, New York, United States

Adams Clinical, Bronx

The Bronx, New York, United States

Adams Clinical, Philadelphia

Philadelphia, Pennsylvania, United States

Adams Clinical, Dallas

DeSoto, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05800925

Related Trials

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT0719650160 locations

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT0585068969 locations

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401106 locations

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT0711532932 locations

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

NCT068207231 location